Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MFGR1877S · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MFGR1877S | DRUG | Intravenous escalating dose |
Inclusion Criteria: * Life expectancy \>/= 12 weeks * ECOG performance status of 0 or 1 * Histologic or cytologic documentation of locally advanced, or metastatic solid malignancy that has relapsed after or failed to respond to at least one prior regimen or for which there is no standard therapy * ...
Top 20 of 25 competitors
MFGR1877S is an investigational small molecule being studied for the treatment of solid tumors and multiple myeloma. It was evaluated in Phase 1 clinical trials for advanced solid tumors and for relapsed or refractory t(4;14)-positive multiple myeloma. The drug is not approved and remains in clinical development.
MFGR1877S is being developed by Roche Holding AG, traded on the OTC market under the ticker RHHBY. Roche is a multinational healthcare company active in pharmaceuticals and diagnostics.
MFGR1877S is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in multiple myeloma and one in solid tumors. The drug is investigational and has not received FDA approval.
MFGR1877S has been studied in two completed Phase 1 trials. NCT01122875 evaluated the drug in patients with relapsed or refractory t(4;14)-positive multiple myeloma, enrolling 14 participants in the United States and Canada. NCT01363024 evaluated the drug in patients with advanced solid tumors, enrolling 24 participants in the United States.
MFGR1877S is the primary name for this investigational drug. No alternative names have been reported for this asset.